Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DZ4LX5
|
|||
| Drug Name |
VY-AADC01
|
|||
| Drug Type |
Gene therapy
|
|||
| Indication | Parkinson disease [ICD-11: 8A00.0; ICD-10: F02.3, G20; ICD-9: 332] | Phase 1 | [1] | |
| Company |
Neurocrine Biosciences
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03065192) An Open-label Safety and Efficacy Study of VY-AADC01 Administered by MRI-Guided Convective Infusion Using a Posterior Trajectory Into the Putamen of Participants With Parkinson's Disease With Fluctuating Responses to Levodopa. U.S.National Institutes of Health. | |||
| REF 2 | Safety of AADC Gene Therapy for Moderately Advanced Parkinson Disease: Three-Year Outcomes From the PD-1101 Trial. Neurology. 2022 Jan 4;98(1):e40-e50. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.